Editorial Comment to Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era

Int J Urol. 2022 Jul;29(7):655. doi: 10.1111/iju.14889. Epub 2022 Mar 31.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Carcinoma, Transitional Cell* / drug therapy
  • Humans
  • Practice Patterns, Physicians'
  • Urologic Neoplasms*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • enfortumab vedotin
  • pembrolizumab